Amino Acid Kinetics of GMP-AA in Healthy Human Volunteers

Amino Acid Kinetics of GMP-AA vs. Phenylalanine-free Amino Acids Compared With Natural Protein in Healthy Adults Volunteers

Children with phenylketonuria (PKU) are treated with a special diet supplemented with a synthetic protein based on amino acids. These have a poor taste and are inefficiently used by the body. A different type of synthetic protein, called glycomacropeptide is being tried in PKU. It tastes better than amino acids but it requires the addition of some extra amino acids which may worsen how well it is absorbed compared with traditional amino acid supplements. We will perform a 3-part trial in healthy adult volunteers to compare amino acids vs glycomacropeptide protein with a 'normal protein' (casein) to examine the absorption properties of these proteins. Volunteers will take one dose of each of the protein sources on 3 different days. Blood and urine samples will be collected examining the rate of absorption of amino acids over 5 hours on each study day.

Study Overview

• Status: Active, not recruiting
• Conditions: Phenylketonurias
• Intervention / Treatment: Dietary supplement: Casein; Dietary supplement: CGMP-AA; Dietary supplement: L-amino acids

Detailed Description

In the USA, casein glycomacropeptide (CGMP), a low phenylalanine (Phe) 64-amino acid peptide derived from cheese whey, is widely promoted as a low Phe protein substitute in phenylketonuria (PKU). Protein substitute is composed of non-essential and essential amino acids which replace natural protein in the diet in order to enable normal growth and suppression of blood Phe levels.

It is suggested that CGMP has a slower absorption than usual protein substitute based on amino acids only (amino acids-AA). This compositional change may enhance protein utilization leading to improved blood Phe control. In PKU, any protein substitute that has its absorption closer to the normal 'physiological state' should be advantageous but pure CGMP is lacking in several essential and conditionally essential amino acids (e.g. tyrosine, leucine, tryptophan, histidine). To ensure that CGMP is safe for PKU, it is supplemented with deficient AA (CGMP-AA). Evidence from 'normal' nutritional research suggests that adding AA to natural protein (similar to CGMP-AA), worsens rather than improves efficiency of protein absorption. It is essential to ascertain if CGMP-AA enhances, worsens or has the same absorption when compared with traditional AA substitutes, particularly when prescribing CGMP-AA for children and maternal PKU. The investigators aim to perform a three-part, randomized, controlled, trial in healthy adult volunteers comparing absorption of CGMP-AA (study product 1) vs. AA (study product 2) vs. normal protein (casein) (study product 3). After overnight fasting, healthy volunteers will consume a standard dose of each of the study products. Over the course of 4 hours, plasma AA will be monitored 8 times and this will provide greater insight into the kinetic absorption of CGMP-AA in PKU. The investigators hope these results will add to existing safety and efficacy data about using CGMP-AA in PKU.

• Study Type: Interventional
• Enrollment (Estimated): 20
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • West Midlands
    • Birmingham, West Midlands, United Kingdom, B15 2TT
      • University Hospitals Birmingham NHS Foundation Trust

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Male and female healthy subjects without PKU;
• 18 to 50 years of age;
• Female subjects with a negative urine pregnancy test prior to entry into the study and who are practicing an adequate method of birth control during the study;
• Good general health status proven by medical history and clinical laboratory values within normal limits or considered not clinically significant by the investigator;
• Non-smokers or not current smokers;
• Body mass index (BMI) between 18 and 30 kg/m2 and weight (kg)
• No existence of disorders or any comorbidity.
• Willing to follow the study protocol and to take the study products;
• Able to understand study procedures and sign informed consent.

Exclusion Criteria:

• History of alcohol or drugs abuse;
• Smokers;
• Women who are pregnant, breast feeding, or planning to become pregnant during the course of the study;
• Received an investigational drug or device within 30 days (or 5 half-lives, whichever is longer) of dosing;
• Existence of any disorder, food allergy or comorbidity (clinically significant including gastrointestinal, renal, pulmonary, hepatic, cardiovascular and endocrine disorders) - to be decided by investigator from medical history;
• Current illness or infection that could interfere with the study;
• Use of laxatives;
• Use of antibiotics in the last 3 months;
• Use of medication that could influence protein metabolism (like growth hormone, anabolic steroids, hormone replacement) - to be judged by the investigator;
• Participation in any clinical trial in the last 3 months;
• Blood donation within the past 3 months;
• On a medically prescribed diet;
• Unable to follow the study protocol or provide consent;
• Unable to take or tolerate one of the study products.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Casein	Dietary supplement: Casein; Natural protein
Active Comparator: Glycomacropeptide	Dietary supplement: CGMP-AA; Glycomacropeptide based protein substitute for Phenylketonuria
Active Comparator: L- amino acids	Dietary supplement: L-amino acids; Synthetic amino acids based protein substitute for Phenylketonuria

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total EAA concentrations	To compare the total EAA concentrations after oral ingestion of one dose of three different protein supplements: cGMP-AA vs. AA only vs. casein.	240 minutes for each protein
Mean CMAX	Mean CMAX within 240 minutes of ingestion of each of the 3 proteins	240 minutes for each protein
AUC of EAA's	AUC of EAA's within 240 minutes of ingestion of each of the 3 proteins	240 minutes for each protein

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Curve characteristics (Cmax)	Curve characteristics (Cmax) of the following quantities: LNAA;; BCAA;; Total AA;; Tyrosine;; Phenylalanine;; Urea;; Insulin.	240 minutes for each protein
Curve characteristics (AUC)	Curve characteristics (AUC) of the following quantities: LNAA;; BCAA;; Total AA;; Tyrosine;; Phenylalanine;; Urea;; Insulin.	240 minutes for each protein

Collaborators and Investigators

• Sponsor: Birmingham Women's and Children's NHS Foundation Trust

Study record dates

Study Major Dates

• Study Start (Actual): October 18, 2022
• Primary Completion (Estimated): August 31, 2023
• Study Completion (Estimated): August 31, 2023

Study Registration Dates

• First Submitted: July 13, 2023
• First Submitted That Met QC Criteria: July 25, 2023
• First Posted (Actual): August 2, 2023

Study Record Updates

• Last Update Posted (Actual): August 2, 2023
• Last Update Submitted That Met QC Criteria: July 25, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Genetic Diseases, Inborn; Metabolism, Inborn Errors; Brain Diseases, Metabolic; Brain Diseases, Metabolic, Inborn; Amino Acid Metabolism, Inborn Errors; Phenylketonurias; Molecular Mechanisms of Pharmacological Action; Chelating Agents; Sequestering Agents; Caseins
• Other Study ID Numbers: 281421

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: All materials, information (oral or written) and unpublished documentation provided to the Investigators (or any company/institution acting on their behalf), including this protocol and the patient Case Report Forms, are the exclusive property of the Research team and may not be given or disclosed, either in part or in whole, by any person to any third party without the prior express consent of the research team. Potential and recruited patients will be identified by a unique study number with only the local research staff having the corresponding list of full patient identifiers, which should be kept secure. CRFs will be labelled with patient initials and their unique study number. Laboratory results shall be labelled similarly having had patient-identifiable details removed. All unpublished information shall be kept confidential and shall not be published or disclosed to a third party without the prior written consent of the research team.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No